SORT-OUT III Trial Shows More Stent Thrombosis With Endeavor Than Cypher
This article was originally published in The Gray Sheet
Executive Summary
New data from Scandinavia suggests Medtronic's Endeavor zotarolimus-eluting stent may be less safe than competing drug-eluting stents
You may also be interested in...
J&J's Cypher Beats Medtronic Endeavor Stent In SORT-OUT III: Does It Matter?
Johnson & Johnson's Cypher sirolimus-eluting stent decidedly outperformed Medtronic'sEndeavor zotarolimus-eluting stent in 18-month, head-to-head data reported last week at the American College of Cardiology annual meeting
J&J's Cypher Beats Medtronic Endeavor Stent In SORT-OUT III: Does It Matter?
Johnson & Johnson's Cypher sirolimus-eluting stent decidedly outperformed Medtronic'sEndeavor zotarolimus-eluting stent in 18-month, head-to-head data reported last week at the American College of Cardiology annual meeting
J&J's Cypher Beats Medtronic Endeavor Stent In SORT-OUT III: Does It Matter?
Medtronic directly disputed the validity of the Cypher results, but at least one interventional cardiologist publicly urged a halt in use of Endeavor based on the data. Several other physicians at the ACC meeting, though, said the study should not have much of an impact on clinical practice in the context of all available data.